
Mediastinum & Esophagus: Case Report

Esophagectomy for Cancer After One Anastomosis Gastric Bypass

Lee Ann Santore, BS,¹
Chris Tarczynski, MSN, RN,²
Mohamad K. Abou Chaar, MD,¹
Omar Ghanem, MD,³ and
Shanda H. Blackmon, MD, MPH¹



(Ann Thorac Surg Short Reports 2023;1:509-511)
© 2023 The Authors. Published by Elsevier Inc. on behalf of The Society of Thoracic Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).


he one anastomosis gastric bypass (OAGB), also referred to as a mini gastric bypass, is a restrictive and hypoabsorptive bariatric procedure to induce weight loss in patients with obesity. It has been gaining popularity since the early 2000s, when it was first described as an alternative to the standard Rouxen-Y gastric bypass¹ by tailoring the stomach into a long tube (pouch) that is anastomosed to jejunum in a loop rather than in a Roux-en-Y configuration. The simplified anatomy of this procedure has been postulated to have decreased morbidity (fewer internal



hernias, Roux stasis syndrome) than the standard Roux-en-Y gastric bypass.² However, it has been suggested that the absence of a Roux in the OAGB allows increased biliary gastritis and gastroesophageal reflux³ and a possible increase in the risk of gastric and esophageal cancers.⁴ The unique anatomy of OAGB patients in whom esophageal cancer develops can make performing a radical esophagectomy challenging. Here we describe the presentation and surgical management of a 53-year-old man with no reflux history before OAGB who was found to have an esophageal mass with associated biliary reflux.

A 53-year-old man with a history of OAGB presented to our clinic for management of newly diagnosed esophageal adenocarcinoma. His OAGB took place 15 years ago and involved a long, 150-cm omega loop of jejunum anastomosed to the distal end of a sleeved stomach pouch (Figure 1), with the remnant greater curve and gastroepiploic vessel intact (Figure 2). He initially presented to an outside hospital with dysphagia and weight loss. An endoscopic ultrasound examination with biopsy specimens revealed the presence of severe bile reflux causing inflammation in the stomach and Los Angeles grade B esophagitis in the lower esophagus as well as a 3-cm tumor in the distal esophagus consistent with invasive, poorly differentiated adenocarcinoma with signet ring esophageal morphology. The tumor was staged as T3 N1 Mo. Immunohistochemistry was negative for human epidermal growth factor receptor 2 (HER2/neu). His programmed cell death ligand 1 combined positive score was 5. He began neoadjuvant chemotherapy consisting of 3 cycles of induction leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX). Positron emission tomography scan showed nearly complete metabolic response in the distal esophagus with a drop of fluorodeoxyglucose from 6.7 to 3.6. A multidisciplinary decision was made to continue with 5-fluorouracil and oxaliplatin during subsequent concurrent radiation (50 Gy in 28 fractions). Thrombocytopenia developed, forcing the patient to skip the last week of radiation and last dose of oxaliplatin. An endoscopic ultrasound examination after neoadjuvant therapy showed scarred mucosa and complete visual resolution of the mass.

We performed a laparoscopic and thoracoscopic Ivor Lewis esophagectomy. We took down the jejunal loop and resected a segment of jejunum followed by primary



reconstruction. We placed a feeding jejunostomy tube and injected 100 IU of Botox into the pylorus. We also performed a mediastinal and abdominal lymphadenectomy. Finally, we resected the sleeved stomach pouch and created a new conduit out of the ischemically conditioned remnant greater curve of the stomach with blood supply from the intact gastroepiploic artery. Once that was complete, we created an esophagogastric anastomosis, with a 25-mm OrVil circular stapler

(Medtronic), and used an omental pedicled graft to buttress around the anastomosis in the event of a leak to prevent esophagobronchial fistula. Just before completion of the anastomosis, a nasogastric tube was placed into the conduit without difficulty. Videotaping of the entire case was performed (Video).

The specimen was sent for pathologic evaluation, which revealed a 1-mm T1b N0 M0 moderately differentiated esophageal adenocarcinoma, with negative margins




FIGURE 2 Three-dimensional reconstruction of patient's (A) isolated venous, (B) isolated arterial, and (C) combined vascular supply after 1 anastomosis gastric bypass. The colored pointing-down triangles indicate the following: violet, superior mesenteric vein; white, gastroepiploic vein; green, superior mesenteric artery; yellow, gastroepiploic artery.




FIGURE 3 Postoperative esophagogram with asterisks highlighting the site of the anastomosis.

and 21 negative nodes. The patient had an uncomplicated postoperative course on our Multidisciplinary Esophagectomy Recovery Initiative Team (MERIT) pathway and normal findings on postoperative esophagography

(Figure 3). He is eating without difficulty and doing well on his 5-month follow-up visit.

COMMENT

The OAGB, although previously thought to be a controversial procedure, is becoming more common because of the decreased technical demand needed by the surgeon with similarly reasonable patient outcomes.5 Hence, we may potentially see increased bile gastritis and gastroesophageal reflux and, consequentially, a potential increase in esophageal cancer in this population of patients.6 The unique anatomy of OAGB makes surgical planning challenging but typically should enable the use of a gastric conduit. The prior separation from the left gastric artery may serve as ischemic preconditioning, possibly making the conduit healthier than if it were created with no prior surgical intervention, as in this case. The ability to use the remnant stomach as the esophageal conduit allows reconstruction that spares the colon⁷ or jejunum, 8 does not require the creation of a microvascular blood supply through "supercharging,"8 and thus allows a less complex procedure with a shorter recovery time. This case report highlights the surgical technique and management as a guide in the event that esophageal cancer develops in OAGB patients.

The Video can be viewed in the online version of this article [https://doi.org/10.1016/j.atssr.2023.03.020] on http://www.annalsthoracicsurgery.org.

FUNDING SOURCES

The authors have no funding sources to disclose.

DISCLOSURES

Shanda Blackmon reports a relationship with Medtronic that includes: consulting or advisory and funding grants; and with STERIS that includes: funding grants. Shanda Blackmon has been issued a patent for an anastomotic esophageal stent.

PATIENT CONSENT

Obtained.

REFERENCES

- 1. Rutledge R, Kular K, Manchanda N. The mini-gastric bypass original technique. *Int J Surg.* 2019;61:38-41.
- 2. Chevallier JM, Arman GA, Guenzi M, et al. One thousand single anastomosis (omega loop) gastric bypasses to treat morbid obesity in a 7-year period: outcomes show few complications and good efficacy. Obes Surg. 2015:25:951-958.
- Keleidari B, Dehkordi MM, Shahraki MS, et al. Bile reflux after one anastomosis gastric bypass surgery: a review study. Ann Med Surg (Lond). 2021;64:102248.
- Runkel M, Runkel N. Esophago-gastric cancer after one anastomosis gastric bypass (OAGB). Chirurgia (Bucur). 2019;114:686-692.
- **5.** Rutledge R, Walsh TR. Continued excellent results with the minigastric bypass: six-year study in 2,410 patients. *Obes Surg.* 2005;15: 1304-1308.
- **6.** Guirat A, Addossari HM. One anastomosis gastric bypass and risk of cancer. *Obes Surg.* 2018;28:1441-1444.
- Kesler KA, Pillai ST, Birdas TJ, et al. "Supercharged" isoperistaltic colon interposition for long-segment esophageal reconstruction. *Ann Thorac Surg*. 2013:95:1162-1169.
- **8.** Gaur P, Blackmon SH. Jejunal graft conduits after esophagectomy. *J Thorac Dis.* 2014;6(suppl 3):S333-S340.